TATodor Arsov

Todor Arsov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Todor Arsov has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    LONGITUDINAL GLOBAL AND DOMAIN-SPECIFIC NEURODEVELOPMENTAL TRAJECTORIES IN SCN1A-RELATED DISORDERS

    by Ljelja Muaremoska Kanzoska, Valentina Dukovska, Todor Arsov

    Pathogenic SCN1A variants are associated with a broad clinical spectrum, ranging from fever-sensitive seizure phenotypes to Dravet syndrome and developmental and epileptic encephalopathies, with highly variable neurodevelopmental outcomes. We aimed to characterize longitudinal global and domain-specific developmental trajectories in a genetically defined pediatric SCN1A cohort. This retrospective longitudinal study included seven children with pathogenic or likely pathogenic SCN1A variants who underwent two age-appropriate Griffiths developmental assessments. General Quotient (GQ), longitudinal change in GQ (ΔGQ), and all available domain-specific subquotients (SQs) were analyzed using version-specific interpretation. The cohort comprised four girls and three boys, with a median age at seizure onset of 10 months (range, 0–48). Fever sensitivity was present in all seven children; six had a history of status epilepticus, and four had drug-resistant epilepsy. Median GQ was 84 (range, 42–100) at the first assessment and 80 (range, 38–98) at follow-up, with marked interindividual variability in longitudinal change (ΔGQ, −21 to +9). Across 14 assessments, 73 domain-specific SQs were available. In the five assessments with globally preserved development, 25 of 26 SQs (96.2%) were within the expected or average range, with no recurrent domain-specific deficit. In contrast, assessments with lower global scores showed predominantly heterogeneous multidomain involvement. These findings highlight marked heterogeneity in longitudinal neurodevelopment across the SCN1A spectrum and support serial assessment of both global and domain-specific development to capture clinically meaningful change over time.

  • Open Access

    Stress-Induced Childhood-Onset Neurodegeneration with Ataxia and Seizures (CONDSIAS) Can Include Severe Primary Hypogonadism

    by Akzam Saidin, Todor Arsov, Zeeshan Shaukat, Rashid Hussain, Benjamin J. Roberts, Gabriela Novotni, Zoran Gucev, Michael G. Ricos, Leanne M. Dibbens

    Pathogenic variants in ADPRS, encoding ADP-ribosylhydrolase 3 (ARH3), cause stress-induced childhood-onset neurodegeneration with variable ataxia and seizures (CONDSIAS; OMIM: 618170), an ultra-rare autosomal recessive disorder with fewer than 61 reported cases worldwide. Here we report a previously undiagnosed 36-year-old who we analysed using trio exome sequencing analysis. We identified a homozygous pathogenic ADPRS variant (NM_017825.3:c.1004T>G; p.Val335Gly), bringing to an end to a 33-year diagnostic odyssey. The patient presented with neurological features consistent with CONDIAS including childhood-onset gait instability, distal sensory-motor axonopathy, and later-emerging cerebellar ataxia with consistently normal brain MRI. However, he also showed with severe primary hypogonadism, including markedly reduced testosterone, elevated gonadotropins, microorchidism, and secondary osteopenia. Although neurological features are well-characterised in CONDSIAS, endocrine involvement has not been emphasized as part of the clinical phenotype. We conducted a literature review of CONDSIAS and report an update on the mutation and clinical spectrum. Our review highlights that endocrine involvement can be part of the phenotype in CONDSIAS . The patient described here has the most severe gonadal phenotype reported to date. Treatment of the patient with testosterone replacement precipitated neurological deterioration on two separate occasions, suggesting that sex hormone supplementation should be carefully considered for ARH3-deficient individuals.

  • Sex in recent gender policies: Interdisciplinary reflections on the X v. North Macedonia case before the ECTHR

    by Elena Ignovska, Todor Arsov

    This article was initially prompted by the inconsistent use of the terms sex and gender in the landmark case X v. the Former Yugoslav Republic of Macedonia (now Republic of North Macedonia) before the European Court of Human Rights (ECtHR). Although the judgment was delivered several years ago, national legal implementation remains incomplete and, to some extent, problematic. This topic remains timely more broadly, given the limited engagement of English legal discourse with the ECtHR's evolving approach to gender recognition. The authors investigate why a seemingly straightforward legal adjustment, such as introducing a gender marker on birth certificates, has proven so contentious. Their inquiry revealed that the term gender, originally introduced to distinguish from sex, has been increasingly subsumed into the concept of sex, often being used interchangeably. The Court's judgment reflects this conflation: at times it refers to sex, at others to gender, and frequently to both (e.g., sex/gender) without clear differentiation. This raises critical questions, foremost among them: Why was there such a concerted effort to establish gender as distinct from sex when some of the same actors now assert that the two are effectively synonymous? While the X v. North Macedonia judgment marks a significant step in affirming transgender rights, it also exposes the ECtHR's ongoing terminological ambiguity. In the absence of clear and consistent language, and in pursuit of fulfilling human rights obligations, particularly under articles 8 and 14 of the ECtHR, a legal compromise has emerged: recognizing gender identity as a fundamental aspect of personal identity, protected under the right to respect for private life.


  • Open Access

    Endocrinologist-led genomic testing for monogenic diabetes in adult diabetes clinics: a feasibility and outcome study

    by Devashree Balasingam, Rosalind Moxham, Sophie Devery, Renee Smyth, Todor Arsov, Nick Olsen, Alexander Viardot, Jerry R Greenfield, Kathy Hc Wu


  • Open Access

    A Novel Pathogenic TUBA1A Variant in a Croatian Infant Is Linked to a Severe Tubulinopathy with Walker–Warburg-like Features

    by Akzam Saidin, Anet Papazovska Cherepnalkovski, Zeeshan Shaukat, Todor Arsov, Rashid Hussain, Ben J. Roberts, Marija Bucat, Klara Cogelja, Michael G. Ricos, Leanne M. Dibbens

    Tubulinopathies are associated with malformations of cortical development but not Walker–Warburg Syndrome. Intensive monitoring of a Croatian infant presenting as Walker–Warburg Syndrome in utero began at 21 weeks due to increased growth of cerebral ventricles and foetal biparietal diameter. Monitoring continued until Caesarean delivery at 34 weeks where the infant was eutrophic. Clinical assessment of a progressive neurological disorder of unknown aetiology found a macrocephalic head and markedly hypoplastic genitalia with a micropenis. Neurological examination showed generalized hypotonia with very rare spontaneous movements, hypotonia-induced respiratory insufficiency and ventilator dependence, and generalized myoclonus intensifying during manipulation. With clinical features of hypotonia, lissencephaly, and brain malformations, Walker–Warburg Syndrome was suspected; however, eye anomalies were absent. Genetic trio analysis via whole-exome sequencing only identified a novel de novo mutation in the TUBA1A gene (NM_006009.4:c.848A>G; NP_006000.2:p.His283Arg) in the infant, who died at 2 months of age, as the likely cause. We report a previously unpublished, very rare heterozygous TUBA1A mutation with clinical features of macrocephaly and hypoplastic genitalia which have not previously been associated with the gene. The absence of eye phenotypes or mutations in Walker–Warburg-associated genes confirm this as not a new presentation of Walker–Warburg Syndrome but a novel TUBA1A tubulinopathy for neonatologists to be aware of.


  • Open Access

    Correction to: Genetic and Epigenetic Basis of Obesity-Induced Inflammation and Diabetes

    by Radoslav Stojchevski, Sara Velichkovikj, Todor Arsov

  • Genetic and Epigenetic Basis of Obesity-Induced Inflammation and Diabetes

    by Radoslav Stojchevski, Sara Velichkovikj, Todor Arsov


  • Ataxia telangiectasia and juvenile idiopathic arthritis: A coincidence or a relationship?

    by Todor Arsov, Mario Sestan, Nastasia Kifer, Alenka Gagro, Matthew Cook, Carola G. Vinuesa, Marija Jelusic


  • Open Access

    Semilobar Holoprosencephaly Caused by a Novel and De Novo ZIC2 Pathogenic Variant

    by D Nonkulovski, A Sofijanova, T Spasovska, Milanovski Gorjan, Lj Muaremoska-Kanzoska, T Arsov

    Holoprosencephaly (HPE) is the most common embryonic forebrain developmental anomaly. It involves incomplete or absent division of the prosencephalon into two distinct cerebral hemispheres during the early stages of organogenesis. HPE is etiologically heterogeneous, and its clinical presentation is very variable. We report a case of a 7 month old female infant, diagnosed with non-syndromic semilobar holoprosencephaly, caused by a novel, de novo pathogenic variant in ZIC2 - one of the most commonly mutated genes in non-syndromic HPE coding for the ZIC2 transcription factor. The patient presented with microcephaly, mild facial dysmorphic features, central hypotonia and spasticity on all four extremities. Ultrasound imaging demonstrated the absence of septum pellucidum, semilobar fusion of the hemispheres and mega cisterna magna and brain MRI with confirmed the diagnosis of HPE. Early diagnosis and management are important for the prevention and treatment of complications associated with this condition.


  • Open Access

    “We’ve opened pandora’s box, haven’t we?” clinical geneticists’ views on ethical aspects of genomic testing in neonatal intensive care

    by T Arsov

    The increasing use of genomic testing in neonatal intensive care units (NICU) gives rise to ethical issues. Yet little is known regarding what health professionals implementing the testing think about its ethical aspects. We therefore explored the views of Australian clinical geneticists towards ethical issues in the use of genomic testing in the Neonatal Intensive care Unit (NICU). Semi-structured interviews with 11 clinical geneticists were conducted, transcribed and analysed thematically. Four themes were identified: 1) Consent: the craft is in the conversation, which encapsulated the challenges in the consent process, and with pre-test counseling; 2) Whose autonomy and who decides? This illustrates the balancing of clinical utility and potentially harms the test, and how stakeholder interests are balanced; 3) The winds of change and ethical disruption, recognizing that while professional expertise is vital to clinical decision-making and oversight of mainstreaming, participants also expressed concern over the size of the genetics workforce and 4). Finding Solutions – the resources and mechanisms to prevent and resolve ethical dilemmas when they arise, such as quality genetic counseling, working as a team and drawing on external ethics and legal expertise. The findings highlight the ethical complexities associated with genomic testing in the NICU. They suggest the need for a workforce that has the necessary support and skills to navigate the ethical terrain, drawing on relevant ethical concepts and guidelines to balance the interests of neonates, their careers and health professionals.